Ontario 2025: OCS THC Potency Testing Pilot Results—Label Accuracy and Supplier Audits

Ontario’s regulated adult-use market has spent the last few years grappling with a problem that’s both technical and reputational: THC inflation—product potency claims that appear higher than what independent or confirmatory testing finds in-market. In response, the Ontario Cannabis Store (OCS) introduced a temporary THC potency testing program targeting high-THC SKUs, starting in early 2024, to verify label claims and build confidence in the wholesale catalog.

By 2025, public reporting and third-party analysis continued to sharpen the focus on label accuracy—particularly for oils and other formats where consumers and regulators expect tight potency control. A frequently cited Canadian analysis of legal oral oil products sold through OCS found a meaningful share fell outside the federal tolerance, raising fresh concerns about consumer deception and quality system gaps.

This post summarizes what the pilot means for 2025–2026 compliance expectations in Ontario, how it intersects with federal potency tolerance rules, and how suppliers can operationalize an audit-ready potency program. It is informational only, not legal advice.

What OCS’s THC potency testing initiative is (and why it matters in 2025)

OCS signaled that its program would be temporary and targeted, focusing on products the OCS QA team identified as “high THC.” The intent was twofold:

• Validate that label potency claims align with test results
• Address broader market concerns that potency on labels—especially for flower—has crept upward in ways that may not reflect reality

Industry coverage in 2024 described the initiative as a pilot involving secondary testing of select products where OCS determined they met an internal “high THC” threshold. (See: StratCann coverage: https://stratcann.com/news/ocs-to-begin-temporary-thc-testing-program-in-2024/)

The compliance implication for 2025 is straightforward: once a wholesale buyer starts doing confirmatory testing, COA quality, lot traceability, and label math become procurement-critical—not just regulatory.

Why the pilot increases business risk even without new legislation

Even when federal rules are unchanged, an OCS-led testing program can affect suppliers through:

• Corrective action requests and timelines
• Supplier notifications and re-testing expectations
• Potential delisting risk (commercial decision) for repeated non-conformance
• Reputational exposure when issues become public through media, consumer discussions, or product action notices

OCS already maintains a structured quality program and communicates expectations via its supplier-facing channels and retailer resources, including quality assurance and recall guidance (for example: https://www.doingbusinesswithocs.ca/faq-quality-assurance/ and https://learn.ocswholesale.ca/cannabis-product-recalls-what-you-need-to-know/).

The federal baseline: potency labeling tolerance and what “out of variance” really means

To understand “mislabeling,” you need to separate three related concepts:

1. Federal potency content rules (what must be on the label)
2. Federal tolerance/accuracy expectations (how close measured potency must be to the claim)
3. Sampling and measurement uncertainty (how results vary by lab method, sample prep, and lot homogeneity)

Health Canada’s packaging and labeling requirements describe what must be disclosed (including total THC/CBD in mg/g or mg/unit, depending on format) and how it must appear. Official guidance: https://www.canada.ca/en/health-canada/services/cannabis-regulations-licensed-producers/packaging-labelling-guide-cannabis-products.html

In addition, the federal regulatory framework includes potency “maintenance” concepts—commonly summarized as an allowable variance window—often discussed in the market as an 80%–120% rule (or similar tolerance framing, depending on the product type and the specific compliance context). The Government of Canada’s regulatory amendments and explanatory materials provide the legal language used for these tolerances. (Example reference: Canada Gazette regulatory text at https://gazette.gc.ca/rp-pr/p2/2025/2025-03-12/html/sor-dors43-eng.html)

Why variance gets complicated for high-THC claims

A product labeled at the extreme high end creates three compounding risks:

• Compression of the feasible range: there’s less room for normal variability if you’re “labeling to the ceiling.”
• Downside exposure: confirmatory testing that reads lower than the claim is what triggers most “inflation” concerns.
• Batch heterogeneity: especially in dried flower, sampling error and non-uniformity can widen dispersion.

OCS’s targeted testing puts a spotlight on whether a brand’s reported total THC is robust across lots, labs, and time.

2025 reporting and third-party findings: variance issues aren’t theoretical

While OCS has not always published SKU-by-SKU pilot results in a single consolidated public dashboard, independent research and media reporting in 2024–2025 reinforced that potency inaccuracies occur in the legal market.

A notable Ontario-focused case series examining legal oral oil products compared labeled THC/CBD versus laboratory testing and found meaningful discrepancies. (Open-access article: https://pmc.ncbi.nlm.nih.gov/articles/PMC11154152/)

Canadian media coverage amplified similar themes, reporting that a significant portion of sampled oils were outside the allowable federal variance. (Example: https://www.auroratoday.ca/local-news/thc-levels-wrong-on-40-of-oils-sold-by-ontario-cannabis-store-lab-testing-shows-9260499)

These findings matter for suppliers because they:

• Strengthen the rationale for OCS confirmatory programs
• Raise the probability of more frequent supplier audits
• Increase retailer sensitivity to potency credibility (and to returns/complaints tied to “doesn’t match label” experiences)

What to expect next: targeted audits, COA verification, and corrective action timelines

OCS has long communicated that it performs quality assurance validation at multiple stages, including product submission and listing, and it provides processes for quality complaints and recalls. (See: https://www.doingbusinesswithocs.ca/faq-quality-assurance/ and retailer guidance materials hosted at https://learn.ocswholesale.ca/.)

Given the direction of travel in 2024–2025, brands operating in Ontario should plan for:

• Targeted re-testing of high-THC lots (especially new lots with unusually high stated potency)
• More scrutiny of COA completeness (methods, lab accreditation context, batch identifiers, results units)
• Requests for raw data packages or underlying lab documentation when results appear inconsistent
• Supplier notification letters with defined timelines to respond, investigate, and implement CAPA
• Commercial outcomes (e.g., temporary holds, reduced replenishment, or delisting) for repeat non-conformance

Even without a public “penalty schedule,” wholesalers can enforce quality expectations through procurement decisions. Suppliers should treat OCS pilot testing as a preview of tighter, more data-driven sourcing norms.

Compliance takeaways for Ontario suppliers: build an audit-ready potency program

The most resilient brands will treat potency as a quality system problem, not a marketing problem. Below is a practical playbook you can adapt for your QMS.

1) Incoming COA validation: make it a gate, not a checkbox

Build a formal COA intake checklist for every lot shipped into Ontario. At minimum, validate:

• Lot/batch identifiers match your ERP/LIMS and packaging records
• Units are correct (mg/g vs mg/unit) and match the label format
• Total THC/Total CBD calculations and rounding rules are consistent
• The lab report includes method identifiers, dates, and sample descriptors
• Any flags or qualifiers are documented and escalated internally

Strong practice: require a second-person review for any lot that is:

• Above an internal “high THC” threshold
• A new product/formulation
• A first lot with a new testing laboratory

2) Confirmatory testing windows: define when you retest and why

OCS’s approach (secondary testing for high-THC products) implies suppliers should have their own confirmatory testing strategy.

Consider adopting:

• Pre-release confirmation for high-risk SKUs (especially those that historically vary)
• Stability or retention sampling at defined intervals for oils and other extracts
• Cross-lab verification when switching labs or methods

Key design choice: set a clear “decision rule” for what happens if the confirmatory result is lower than the label claim.

3) Variance thresholds: use internal tighter limits than the federal ceiling

If you aim to be “barely compliant,” you’re exposed to normal measurement variance, sampling variability, and lab-to-lab differences.

A safer strategy is to implement internal action limits tighter than the federal tolerance. For example:

• Create a “yellow zone” well before the regulatory edge
• Trigger CAPA investigations when results trend downward across consecutive lots
• Require QA sign-off before any label claim increase above a defined step change (e.g., moving from mid-20s to high-20s)

This is especially important under the focus keyword context of OCS THC testing 2025: confirmatory programs tend to concentrate on outliers.

4) Third-party lab selection: document independence, method fit, and competence

Potency inflation discussions often end up implicating labs—fairly or unfairly. The business risk is that your supply chain partners and buyers will expect you to defend your data.

Tighten your lab qualification process:

• Document method validation fit for the product matrix (flower vs oil vs resin, etc.)
• Use written quality agreements addressing retests, OOS investigations, and data integrity
• Retain raw data packages, chromatograms, and calculation worksheets when available
• Review lab performance with periodic trend reports

If OCS requests documentation, you want to respond with a complete, organized package rather than scrambling.

5) Lot-specific labeling controls: stop treating potency as a static marketing claim

High-THC marketing creates pressure to push the top number. But under a confirmatory testing environment, the label must be defensible.

Operational controls to consider:

• Tie label generation to the specific lot COA (not a “typical potency” value)
• Implement a controlled rounding policy (and audit it)
• For product types where ranges are permitted or used, ensure the range statement is supported by lot data and doesn’t conflict with the specific lot COA
• Create an internal “label pre-audit” step before printing or applying labels

Health Canada’s labeling guide is the canonical reference for formatting and required information (https://www.canada.ca/en/health-canada/services/cannabis-regulations-licensed-producers/packaging-labelling-guide-cannabis-products.html). OCS also provides Ontario-channel specific guidance and updates via its wholesale learning portal (https://learn.ocswholesale.ca/).

Rapid-response SOP: relabel, withdraw, or hold—without chaos

If confirmatory testing (yours or OCS’s) indicates an issue, speed and structure matter. Build a rapid-response SOP that covers:

Trigger events

• OCS notification of a potency variance concern
• Internal confirmatory result outside internal action limits
• Retailer complaint patterns suggesting label mismatch

First 48 hours actions

• Quarantine affected lots (physical and system holds)
• Assemble an incident team: QA, Regulatory, Supply Chain, Sales, and Communications
• Pull the document packet: COAs, raw data, batch record, label proofs, distribution list
• Draft a buyer-facing summary: what happened, what lots, preliminary scope, next steps

Investigation and CAPA

• Conduct an OOS/OOT investigation (including sampling plan review)
• Assess whether the issue is: lab method, sampling representativeness, calculation/rounding, or true process drift
• Define CAPA with owner, due dates, and effectiveness checks

Decision outcomes

Depending on severity and direction from partners:

• Relabel (if permitted and feasible)
• Stop sale / withdrawal from distribution channels
• Recall process if required by Health Canada or initiated voluntarily

For Ontario retailers, OCS provides practical recall handling guidance (https://learn.ocswholesale.ca/cannabis-product-recalls-what-you-need-to-know/). Align your SOP to those workflows so retailers aren’t improvising.

Retailers and consumers in Ontario: what this means on the ground

Even though suppliers feel the most direct procurement pressure, the downstream impact is significant.

For retailers

• Expect more potency-related customer questions
• Train staff to avoid over-reliance on “headline THC” and to communicate variability responsibly
• Ensure your store has a clear process for documenting quality complaints and routing them through the right channels

OCS’s retailer learning portal includes guidance on submitting quality assurance claims and responding to recalls (https://learn.ocswholesale.ca/submitting-a-product-quality-assurance-claim/).

For consumers

• Potency numbers are not a guarantee of experience
• For oils and other ingestible formats, label accuracy is especially important for dosing
• Watch for updates from official sources if a product action occurs

Consumers can reference product information and notices through official channels such as https://ocs.ca/.

Enforcement context in Ontario: roles of OCS, AGCO, and Health Canada

It helps to distinguish responsibilities:

• Health Canada sets and enforces federal production, testing, packaging, and labeling rules.
• OCS is Ontario’s wholesale buyer and online retailer, and can set commercial quality requirements and validation programs for products it lists.
• AGCO regulates Ontario retail licensing and retail store standards.

AGCO’s retail regulation guide is the authoritative starting point for Ontario retail compliance context: https://www.agco.ca/en/cannabis/cannabis-retail-regulation-guide

In practice, potency label accuracy issues can trigger different pathways: internal supplier CAPA, wholesale delisting decisions, voluntary withdrawals, or formal recall processes where applicable.

What to watch in 2026: procurement, QA manuals, and “By the Numbers” style reporting

Based on how the market has evolved, compliance teams should monitor for:

• Updates to OCS supplier onboarding expectations and QA validation language in OCS supplier-facing documentation
• Continued targeted testing focused on categories most prone to perceived inflation (high-THC flower and select extract formats)
• More public storytelling around market integrity via OCS reporting and media coverage

OCS publishes ongoing updates and resources through:

• Doing Business with OCS: https://www.doingbusinesswithocs.ca/
• OCS Wholesale Learn portal: https://learn.ocswholesale.ca/
• OCS newsroom/blog: https://ocs.ca/blogs/news

Practical checklist: be ready for OCS THC testing in 2025-style audits

Use this short checklist to benchmark readiness:

• We have a documented COA verification procedure for every lot
• High-THC SKUs follow a defined confirmatory testing plan
• We qualify and re-qualify labs; we can produce raw data packages on request
• Labels are generated from lot-specific data with controlled rounding and approvals
• We maintain a potency trend dashboard and investigate drift early
• We have a written relabel/withdrawal SOP with 48-hour actions and communication templates

Bottom line

The OCS temporary potency testing pilot—and the 2025 attention on label accuracy—signals a market where potency credibility is becoming a core element of cannabis compliance, wholesale competitiveness, and consumer trust in Ontario.

Brands that treat potency as a governed, auditable process—complete with COA validation, confirmatory testing, and rapid-response SOPs—will be best positioned to avoid delistings, limit public incidents, and build durable relationships with buyers.

To keep your organization current on Ontario and federal requirements, build audit-ready SOPs, and track evolving expectations like OCS THC testing 2025, use https://cannabisregulations.ai/ for compliance intelligence and operational playbooks.